1. Home
  2. OMCL vs HROW Comparison

OMCL vs HROW Comparison

Compare OMCL & HROW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Omnicell Inc. ($0.001 par value)

OMCL

Omnicell Inc. ($0.001 par value)

N/A

Current Price

$35.93

Market Cap

1.6B

Sector

Technology

ML Signal

N/A

HROW

Harrow Inc.

N/A

Current Price

$29.39

Market Cap

1.7B

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
OMCL
HROW
Founded
1992
1998
Country
United States
United States
Employees
N/A
N/A
Industry
Computer Manufacturing
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.6B
1.7B
IPO Year
2000
2008

Fundamental Metrics

Financial Performance
Metric
OMCL
HROW
Price
$35.93
$29.39
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
8
9
Target Price
$57.86
★ $65.00
AVG Volume (30 Days)
471.9K
★ 601.4K
Earning Date
10-29-2026
11-09-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
★ 71.43
EPS
★ 0.77
N/A
Revenue
★ $787,309,000.00
N/A
Revenue This Year
$4.40
$28.59
Revenue Next Year
$4.15
$53.17
P/E Ratio
$46.55
★ N/A
Revenue Growth
★ 9.93
N/A
52 Week Low
$29.06
$27.00
52 Week High
$51.84
$54.98

Technical Indicators

Market Signals
Indicator
OMCL
HROW
Relative Strength Index (RSI) 60.63 24.99
Support Level $35.25 $28.54
Resistance Level $37.96 $35.87
Average True Range (ATR) 0.98 1.29
MACD 0.40 -0.03
Stochastic Oscillator 96.43 30.30

Price Performance

Historical Comparison
OMCL
HROW

About OMCL Omnicell Inc. ($0.001 par value)

Omnicell Inc provides automation and business analytics software for healthcare providers. The company is engaged in transforming the pharmacy and nursing care delivery model. The company helps its customers define and deliver cost-effective medication management designed to equip and empower pharmacists and nurses to focus on patient care rather than administrative tasks and drive improved clinical, operational, and financial outcomes across all care settings. The company derives the majority of its revenue from the United States.

About HROW Harrow Inc.

Harrow Inc is an eyecare pharmaceutical company engaged in the discovery, development, and commercialization of ophthalmic pharmaceutical products for the U.S. market. The company partners with U.S. eyecare professionals to develop products used to manage ophthalmic conditions affecting both the front and back of the eye, such as dry eye disease, cataracts, refractive errors, glaucoma, etc. Its portfolio of branded ophthalmic pharmaceuticals includes Iheezo, Vevye, Byooviz Opuviz, Natacyn, Maxitrol, Maxidex, etc. Additionally, the company's development pipeline comprises candidates like MELT-300, H-N08, CR-01, and MELT-210, being developed to address unmet needs in eye care and selected adjacent markets. Its reportable segments are: Branded, which derives maximum revenue, and ImprimisRx.

Share on Social Networks: